Clinical Utility of β-Hydroxybutyrate vs Anion Gap to Define Resolution of Diabetic Ketoacidosis
American Journal of Critical Care · 01.07.2026 · 35 (4) · 298-303
DOI: 10.4037/ajcc2026208 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift American Journal of Critical Care, erschienen am 01.07.2026. Verfasst von Alexandra Cyr und 4 weiteren Autor:innen. Beteiligte Einrichtung: Alexandra Cyr is a critical care pharmacy specialist, SSM St Anthony Hospital Department of Pharmacy, Oklahoma City, Oklahoma. At the time of writing…. Hauptthemen laut MEDLINE: Diabetic Ketoacidosis, 3-Hydroxybutyric Acid, Acid-Base Equilibrium. Die Arbeit nennt 9 Literaturangaben.
Abstract (Originalsprache)
Background
Updated guidelines for managing diabetic ketoacidosis (DKA) preferentially recommend using β-hydroxybutyrate instead of anion gap for determining DKA resolution. Although physiological reasons suggest benefits of β-hydroxybutyrate over anion gap, clinical data supporting this idea are limited.
Objective
To compare time to DKA resolution (time from initial intravenous insulin to first dose of long-acting subcutaneous insulin) between patients managed with β-hydroxybutyrate and patients managed with anion gap.
Methods
This retrospective study evaluated patients with DKA who were managed with the same continuous intravenous insulin protocol at 2 participating sites, one that used β-hydroxybutyrate and the other that used anion gap to assess resolution. The primary outcome was time to first dose of long-acting insulin, with secondary outcomes including incidence of DKA recurrence after transition to subcutaneous insulin.
Results
A total of 178 patients were included, with 89 in the β-hydroxybutyrate–managed arm. Baseline characteristics, including DKA severity, were similar in the 2 groups. Conversion to a long-acting insulin regimen occurred at a median (IQR) of 23.5 (17.9-31.0) hours in the β-hydroxybutyrate group and 13.3 (10.0-18.2) hours in the anion gap group (P < .01) with no difference in rates of DKA recurrence.
Conclusions
Monitoring anion gap rather than β-hydroxybutyrate for DKA resolution led to shorter time on an insulin infusion with no increase in DKA recurrence. Prospective studies evaluating β-hydroxybutyrate thresholds or how to best use β-hydroxybutyrate in practice are warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Alexandra Cyr is a critical care pharmacy specialist, SSM St Anthony Hospital Department of Pharmacy, Oklahoma City, Oklahoma. At the time of writing, she was a PGY-2 critical care pharmacy resident at Texas Health Pres…
- Andrew Faust is a critical care pharmacy specialist, Department of Pharmacy, Texas Health Presbyterian Hospital, Dallas, Texas.
- Margarita Taburyanskaya is a critical care pharmacy specialist, Texas Health Harris Methodist Hospital, Department of Pharmacy, Fort Worth, Texas.
- Thomas Brad Raper is an attending intensivist, Sound Pulmonary Critical Care Group, Dallas, Texas.
- Anthony Ortegon is an attending intensivist, Sound Pulmonary Critical Care Group, Dallas, Texas.
Zitieren
APA
Cyr, A., Faust, A., Taburyanskaya, M., Raper, T. B., & Ortegon, A. (2026). Clinical Utility of β-Hydroxybutyrate vs Anion Gap to Define Resolution of Diabetic Ketoacidosis. American Journal of Critical Care, 35(4), 298-303. https://doi.org/10.4037/ajcc2026208
Vancouver
Cyr A, Faust A, Taburyanskaya M, Raper TB, Ortegon A. Clinical Utility of β-Hydroxybutyrate vs Anion Gap to Define Resolution of Diabetic Ketoacidosis. American Journal of Critical Care. 2026;35(4):298-303. doi:10.4037/ajcc2026208
BibTeX
@article{Cyr2026,
author = {Cyr, Alexandra and Faust, Andrew and Taburyanskaya, Margarita and Raper, Thomas Brad and Ortegon, Anthony},
title = {Clinical Utility of β-Hydroxybutyrate vs Anion Gap to Define Resolution of Diabetic Ketoacidosis},
journal = {American Journal of Critical Care},
year = {2026},
volume = {35},
number = {4},
pages = {298--303},
doi = {10.4037/ajcc2026208}
}
EUVIMED